Viewing Study NCT05091567


Ignite Creation Date: 2025-12-25 @ 12:31 AM
Ignite Modification Date: 2026-02-07 @ 1:54 AM
Study NCT ID: NCT05091567
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-22
First Post: 2021-10-12
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Sponsor: Hoffmann-La Roche
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Small-Cell Lung Cancer View
Keywords: